| Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, ... The Lancet 398 (10306), 1157-1169, 2021 | 208 | 2021 |
| A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. RQ Hintzen, R De Jong, CE Hack, M Chamuleau, EF De Vries, ... Journal of immunology (Baltimore, Md.: 1950) 147 (1), 29-35, 1991 | 159 | 1991 |
| High INDO (indoleamine 2, 3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome M Chamuleau, A van de Loosdrecht, C Hess, J Janssen, A Zevenbergen, ... haematologica 93 (12), 1894-1898, 2008 | 131 | 2008 |
| Venetoclax plus R-or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial AD Zelenetz, G Salles, KD Mason, C Casulo, S Le Gouill, LH Sehn, H Tilly, ... Blood, The Journal of the American Society of Hematology 133 (18), 1964-1976, 2019 | 130 | 2019 |
| Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment TM Westers, C Alhan, MED Chamuleau, MJDL van der Vorst, C Eeltink, ... Blood, The Journal of the American Society of Hematology 115 (9), 1779-1784, 2010 | 109 | 2010 |
| Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis M Federico, MDC Barrigón, L Marcheselli, V Tarantino, M Manni, ... The Lancet Haematology 5 (8), e359-e367, 2018 | 104 | 2018 |
| Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome MED Chamuleau, Y Souwer, SM Van Ham, A Zevenbergen, TM Westers, ... Cancer research 64 (16), 5546-5550, 2004 | 93 | 2004 |
| Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome MED Chamuleau, TM Westers, L van Dreunen, J Groenland, ... haematologica 94 (4), 496, 2009 | 92 | 2009 |
| Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with … M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, ... Blood 136, 45-46, 2020 | 68 | 2020 |
| High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2 MED Chamuleau, GJ Ossenkoppele, A Van Rhenen, L Van Dreunen, ... Leukemia research 35 (6), 741-749, 2011 | 58 | 2011 |
| Superior activity of fusion protein scFvRit: sFasL over cotreatment with rituximab and Fas agonists E Bremer, B ten Cate, DF Samplonius, N Mueller, H Wajant, AJ Stel, ... Cancer research 68 (2), 597-604, 2008 | 58 | 2008 |
| Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989–2010 DE Issa, SAM van de Schans, MED Chamuleau, HE Karim-Kos, ... Haematologica 100 (4), 525, 2015 | 55 | 2015 |
| MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation MED Chamuleau, GJ Ossenkoppele, AA Van De Loosdrecht Immunobiology 211 (6-8), 619-625, 2006 | 55 | 2006 |
| Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment HJ van der Horst, AV de Jonge, IH Hiemstra, AT Gelderloos, DRAI Berry, ... Blood cancer journal 11 (2), 38, 2021 | 49 | 2021 |
| European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma PL Zinzani, L Karlin, J Radford, D Caballero, P Fields, MED Chamuleau, ... Haematologica 101 (10), e407, 2016 | 49 | 2016 |
| DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies SC Oostindie, HJ van der Horst, LP Kil, K Strumane, MB Overdijk, ... Blood cancer journal 10 (3), 30, 2020 | 47 | 2020 |
| CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering SC Oostindie, HJ Van Der Horst, MA Lindorfer, EM Cook, JC Tupitza, ... haematologica 104 (9), 1841, 2019 | 47 | 2019 |
| Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens LEM Oosten, MED Chamuleau, FW Thielen, LC de Wreede, C Siemes, ... Annals of hematology 97, 255-266, 2018 | 46 | 2018 |
| Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies HJ van der Horst, IS Nijhof, T Mutis, MED Chamuleau Cancers 12 (10), 3041, 2020 | 45 | 2020 |
| Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial MED Chamuleau, CN Burggraaff, M Nijland, K Bakunina, R Mous, ... haematologica 105 (12), 2805, 2020 | 41 | 2020 |
